NPM1-mutated AML: Targeting by disassembling

Abstract

In this issue of Blood, Balusu and collegues provide preclinical evidences that targeting nucleophosmin (NPM1) induces differentiation and death of acute myeloid leukemia (AML) cells harboring NPM1 mutations.1 These findings establish the rationale for novel treatment strategies in this large subgroup of AML.